In a phase 3 clinical study, compared with subcutaneous injection of GM-CSF alone, intratumoral injection of engineered T-VEC into melanoma metastases considerably improved the survival time of patients bearing advanced melanoma [17]. Here, CSF2 is linked to melanoma.